Report
Karen Andersen
EUR 100.00 For Business Accounts Only

Maintaining Our Takeda FVE Following Strong Results in Fiscal 1H

Takeda's underlying revenue (at constant currencies, excluding one-time items and divestitures) grew 4.2% in the first half of the firm's fiscal 2018, with 31.8% core earnings growth as margin expansion drove strong bottom-line results. Takeda raised its outlook for the full fiscal year as Velcade generic competition is further delayed to March 2019 (JPY 35.5 billion higher sales expected for the year) and as the firm is seeing strong operating expense control, and we found the projected net deb...
Underlying
Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical is a public company incorporated in Japan. Co. and its subsidiaries is a global pharmaceutical group and is engaged in the research, development, manufacturing and marketing of pharmaceutical products, over-the-counter (“OTC”) medicines and quasi-drug consumer products, and other healthcare products. Co.'s principal pharmaceutical products include medicines in the following therapeutic areas: gastroenterology, oncology and neuroscience.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Karen Andersen

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch